Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: Cutaneous T-Cell Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Welcome to The Cutaneous T-Cell Lymphoma (CTCL) Channel

VJHemOnc brings you important developments in the field of CTCL presented by esteemed experts from around the world. The CTCL Channel offers exclusive video interviews as well as podcasts and in-depth roundtable discussions so you can keep up with the latest wherever you are.

The CTCL Channel covers all key research areas including insightful views on managing Sézary syndrome, systemic therapies including antibody-drug conjugates, novel clinical trial data, and much more.

Improved understanding of CTCL disease biology 3:09
Improved understanding of CTCL disease biology
Pierluigi Porcu • 12 Sep 2018
Promising treatments in CTCL 4:22
Promising treatments in CTCL
Pierluigi Porcu • 12 Sep 2018
MAVORIC trial: mogamulizumab for R/R CTC 2:31
MAVORIC trial: mogamulizumab for R/R CTC
Pierluigi Porcu • 12 Sep 2018
Novel therapies on the horizon for cutaneous T-cell lymphoma 2:05
Novel therapies on the horizon for cutaneous T-cell lymphoma
Rudolf Stadler • 27 Sep 2018
Checkpoint inhibitors for cutaneous lymphoma: the way of the future? 1:17
Checkpoint inhibitors for cutaneous lymphoma: the way of the future?
Christiane Querfeld • 27 Sep 2018
Novel diagnostics & biomarkers for DLBCL and CTCL 8:01
Novel diagnostics & biomarkers for DLBCL and CTCL
Bjoern Chapuy et al. • 21 Sep 2018
Pre-clinical activity of tipifarnib in CTCL 2:12
Pre-clinical activity of tipifarnib in CTCL
Pierluigi Porcu • 12 Sep 2018
Antagomir for cutaneous T-cell lymphoma: promising trial results 2:22
Antagomir for cutaneous T-cell lymphoma: promising trial results
Christiane Querfeld • 9 Dec 2017
Immune checkpoint inhibitors for cutaneous T-cell lymphoma 1:48
Immune checkpoint inhibitors for cutaneous T-cell lymphoma
Christiane Querfeld • 9 Dec 2017
Targeted Antibody Mogamulizumab Superior to Vorinostat for Previously Treated CTCL 7:09
Targeted Antibody Mogamulizumab Superior to Vorinostat for Previously Treated CTCL
Youn H. Kim • 10 Dec 2017
Combining targeted agents with checkpoint inhibitors in cutaneous T-cell lymphoma 1:33
Combining targeted agents with checkpoint inhibitors in cutaneous T-cell lymphoma
Francine Foss • 10 Sep 2017
Escalating doses and improving outcomes in cutaneous T-cell lymphomas 1:24
Escalating doses and improving outcomes in cutaneous T-cell lymphomas
Martine Bagot • 14 Jun 2017
Monoclonal antibody therapies for cutaneous T-cell lymphoma 2:22
Monoclonal antibody therapies for cutaneous T-cell lymphoma
Pier L. Zinzani • 3 Oct 2015

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Diamond Supporter

AstraZeneca

Gold Supporter

BMS Johnson & Johnson

Silver Supporter

Takeda

Bronze Supporter

Galapagos

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals